Literature DB >> 15068861

Mouse strain-dependent differences in enhancement of immune responses by C3d.

Franklin R Toapanta1, Ted M Ross.   

Abstract

Our laboratory has demonstrated that conjugating the complement protein, C3d, to an antigen is an effective method for eliciting high titer, long-lasting antibodies. The use of C3d as a molecular adjuvant is quite effective in enhancing the efficacy of DNA vaccines expressing the envelope (Env) protein of the human immunodeficiency virus (HIV). However, our previous studies have examined the effectiveness of C3d conjugated vaccines in BALB/c mice. In this study, one outbred strain and three different inbred strains of mice were vaccinated with plasmids expressing a secreted form of Env (sgp120) fused to two or three copies of the murine homologue of C3d (mC3d). Analyses of titers demonstrated that sgp120 conjugated to multiple copies of C3d induced similar high titer anti-Env antibodies in all mouse strains tested. However, the immunoglobulin subclass elicited in inbred mice vaccinated with sgp120-mC3d-DNA was predominately IgG(1), but was a mixture of IgG(1) and IgG(2a) in vaccinated outbred mice. Also, splenocytes from all sgp120-mC3d-DNA vaccinated inbred mouse strains secreted primarily interleukin-4 (IL-4) indicating a T helper (Th) type 2 response. In contrast, mice vaccinated with sgp120-mC3d-DNA had splenocytes that secreted both IL-4 and interferon-gamma (INF-gamma) indicating a mixed T helper response. In addition, the avidity maturation of the anti-Env antisera was enhanced in outbred mice with DNA expressing sgp120-mC3d. Overall, C3d conjugated DNA vaccines elicited enhanced immune responses in outbred mice compared to inbred mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068861     DOI: 10.1016/j.vaccine.2003.10.050

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.

Authors:  Kelly R Young; Benjamin E Teal; Yvonne Brooks; Thomas D Green; Joseph F Bower; Ted M Ross
Journal:  AIDS Res Hum Retroviruses       Date:  2004-11       Impact factor: 2.205

3.  C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.

Authors:  Joseph F Bower; Kelly L Sanders; Ted M Ross
Journal:  Curr HIV Res       Date:  2005-04       Impact factor: 1.581

4.  Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus.

Authors:  Zhenhua Zhang; Yongqing Li; Shufang Xu; Fuyong Chen; Li Zhang; Beiyu Jiang; Xiaoling Chen
Journal:  Virol J       Date:  2010-05-09       Impact factor: 4.099

5.  Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Authors:  Matthew D Dunn; Shannan L Rossi; Donald M Carter; Matthew R Vogt; Erin Mehlhop; Michael S Diamond; Ted M Ross
Journal:  Virol J       Date:  2010-05-12       Impact factor: 4.099

6.  Transcriptional profiling of murine organ genes in response to infection with Bacillus anthracis Ames spores.

Authors:  Scott T Moen; Linsey A Yeager; William S Lawrence; Cindy Ponce; Cristi L Galindo; Harold R Garner; Wallace B Baze; Giovanni Suarez; Johnny W Peterson; Ashok K Chopra
Journal:  Microb Pathog       Date:  2007-10-23       Impact factor: 3.738

7.  C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.

Authors:  Franklin R Toapanta; Dilhari R DeAlmeida; Matthew D Dunn; Ted M Ross
Journal:  Immunol Lett       Date:  2010-01-12       Impact factor: 3.685

8.  A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

Authors:  David F Gardiner; Talia Rosenberg; Jerry Zaharatos; David Franco; David D Ho
Journal:  Vaccine       Date:  2009-04-09       Impact factor: 3.641

9.  Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.

Authors:  Corey J Crevar; Ted M Ross
Journal:  Virol J       Date:  2008-10-28       Impact factor: 4.099

10.  Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.

Authors:  Rick A Bright; Donald M Carter; Corey J Crevar; Franklin R Toapanta; Jonathan D Steckbeck; Kelly S Cole; Niranjan M Kumar; Peter Pushko; Gale Smith; Terrence M Tumpey; Ted M Ross
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.